CA2304119A1 - Modulation de reactions immunitaires - Google Patents
Modulation de reactions immunitaires Download PDFInfo
- Publication number
- CA2304119A1 CA2304119A1 CA002304119A CA2304119A CA2304119A1 CA 2304119 A1 CA2304119 A1 CA 2304119A1 CA 002304119 A CA002304119 A CA 002304119A CA 2304119 A CA2304119 A CA 2304119A CA 2304119 A1 CA2304119 A1 CA 2304119A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- immune
- animal
- alkyl
- alkenyl groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne un procédé permettant d'influencer ou de moduler chez un animal une stimulation ou une suppression du produit de cellules immunitaires, suite à une réaction immunitaire à un stimulant immunitaire externe ou endogène. Le procédé comporte les étapes consistant à administrer à cet animal une quantité efficace du point de vue d'une modulation immunitaire, et non toxique, d'un composé sélectionné dans le groupe constitué par des composés représentés par la formule (I) chimique générale: R¿1?-CO-NR¿2?R¿3? (I), dans laquelle R¿1? est sélectionné dans le groupe constitué par H, un groupe alkyle inférieur (c.-à-d. C¿1? à C¿3?) et un groupe alcényle C¿2? à C¿3?; R¿2? et R¿3? sont les mêmes ou différents, et chacun est sélectionné dans le groupe constitué par H, un groupe alkyle inférieur (c.-à-d. C¿1? à C¿3?) et un groupe alcényle C¿2? à C¿3? qui peuvent être éventuellement halogénés ou hydroxylés, ou lorsqu'ils sont combinés l'un avec l'autre, peuvent former un groupe -(CH¿2?)¿n? dans lequel n est un nombre compris entre 2 et 5, ou le groupe -(CH¿2?)¿2?-O-(CH¿2?)¿2?, des métabolites ou des promédicaments de ceux-ci. Le procédé est utile pour traiter diverses affections associées à des réactions immunitaires inappropriées. L'invention concerne l'utilisation de composés représentés par la formule (I) pour fabriquer des médicaments utiles pour le traitement de telles affections, et des préparations pharmaceutiques renfermant ceux-ci.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA97/8319 | 1997-09-16 | ||
ZA978319 | 1997-09-16 | ||
PCT/US1998/019126 WO1999013885A1 (fr) | 1997-09-16 | 1998-09-16 | Modulation de reactions immunitaires |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2304119A1 true CA2304119A1 (fr) | 1999-03-25 |
Family
ID=25586589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002304119A Abandoned CA2304119A1 (fr) | 1997-09-16 | 1998-09-16 | Modulation de reactions immunitaires |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1019063A4 (fr) |
JP (1) | JP2001516721A (fr) |
CN (1) | CN1279612A (fr) |
AU (1) | AU737867B2 (fr) |
BR (1) | BR9812321A (fr) |
CA (1) | CA2304119A1 (fr) |
IL (1) | IL135091A0 (fr) |
NO (1) | NO20001341L (fr) |
NZ (1) | NZ503418A (fr) |
WO (1) | WO1999013885A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2324631A1 (fr) * | 2000-10-26 | 2002-04-26 | Virodene Pharmaceutical Holdings (Proprietary) Limited | Substance ou composition pour le traitement du cancer |
WO2005053641A1 (fr) * | 2003-12-05 | 2005-06-16 | Namibia Medical Investments (Pty) Limited | Timbre |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814659A (en) * | 1996-04-23 | 1998-09-29 | Dtr Dermal Therapy (Barbados) Inc. | Topical analgesic composition |
-
1998
- 1998-09-16 CA CA002304119A patent/CA2304119A1/fr not_active Abandoned
- 1998-09-16 WO PCT/US1998/019126 patent/WO1999013885A1/fr not_active Application Discontinuation
- 1998-09-16 AU AU93890/98A patent/AU737867B2/en not_active Ceased
- 1998-09-16 NZ NZ503418A patent/NZ503418A/xx not_active IP Right Cessation
- 1998-09-16 JP JP2000511505A patent/JP2001516721A/ja active Pending
- 1998-09-16 CN CN98810397A patent/CN1279612A/zh active Pending
- 1998-09-16 BR BR9812321-1A patent/BR9812321A/pt not_active IP Right Cessation
- 1998-09-16 EP EP98946998A patent/EP1019063A4/fr not_active Withdrawn
- 1998-09-16 IL IL13509198A patent/IL135091A0/xx unknown
-
2000
- 2000-03-15 NO NO20001341A patent/NO20001341L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1279612A (zh) | 2001-01-10 |
WO1999013885A1 (fr) | 1999-03-25 |
NZ503418A (en) | 2001-02-23 |
JP2001516721A (ja) | 2001-10-02 |
EP1019063A1 (fr) | 2000-07-19 |
AU737867B2 (en) | 2001-09-06 |
IL135091A0 (en) | 2001-05-20 |
EP1019063A4 (fr) | 2003-09-03 |
NO20001341D0 (no) | 2000-03-15 |
NO20001341L (no) | 2000-05-16 |
AU9389098A (en) | 1999-04-05 |
BR9812321A (pt) | 2000-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kaufman | Clinical cure of herpes simplex keratitis by 5-iodo-2'-deoxyuridine | |
Porozov et al. | Inhibition of IL‐1β and TNF‐α Secretion from Resting and Activated Human Immunocytes by the Homeopathic Medication Traumeel® S | |
TW438588B (en) | Topical ophthalmic formulations for treating allergic eye diseases | |
ES2240163T3 (es) | Utilizaciones terapeuticas de polimeros y de oligomeros a base de gamma-hidroxibutirano (ghb). | |
Wu et al. | Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice | |
Li et al. | Contribution of the P2X4 receptor in rat hippocampus to the comorbidity of chronic pain and depression | |
Palin et al. | The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFα-induced sickness behavior | |
Olianas et al. | Inhibition of TNF-α-induced neuronal apoptosis by antidepressants acting through the lysophosphatidic acid receptor LPA1 | |
Kusher et al. | Effect of the psychoactive metabolite of marijuana, Δ9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes | |
JPH11504050A (ja) | 生物学的応答修飾因子としての双性イオンの組成物及び方法 | |
Constantin et al. | Sulfatides trigger cytokine gene expression and secretion in human monocytes | |
AU737867B2 (en) | Modulation of immune responses | |
Nathanson et al. | Diffusion of Sulfonamides and Penicillin into Fibrin. | |
Quan et al. | Aquaporins in Immune System | |
Klein et al. | Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice | |
CN101701218B (zh) | 一种抑制Th1和Th17分化的免疫调节性寡聚脱氧核苷酸及应用 | |
Chang | Mechanism of action of colchicine. II. Effects of colchicine and its analogs on phagocytosis and chemotaxis in vitro. | |
CN1329497A (zh) | 对乙型肝炎病毒的联合治疗 | |
Meyler et al. | The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. | |
Mondino et al. | Complement inhibitors in normal cornea and aqueous humor. | |
CN105311636B (zh) | 一种抗疱疹病毒软膏剂及其制备方法 | |
ES2281195T3 (es) | Factores inmunomoduladores para el tratamiento inmunosupresor y antialergico. | |
US11944601B2 (en) | Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation | |
WO2014191822A1 (fr) | Dérivés d'acide benzoïque utilisés en tant qu'inhibiteurs des récepteurs il-15 rα | |
RU2008902C1 (ru) | Способ лечения туберкулеза легких с преимущественно экссудативным типом воспаления |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |